AbbVie report to update hepatitis C drug war

By Bob Herman  |  April 18, 2015

Pharmaceutical company AbbVie will unveil its first-quarter earnings Thursday, giving investors and industry observers their first glimpse of what a full quarter of sales looks like for its new hepatitis C treatment.

Specialty drugs, Medicaid expansion drive jump in prescription spending

By Steven Ross Johnson  |  April 14, 2015

Spending in the U.S. on prescription drugs rose by 13% in 2014, driven largely by increased spending on new breakthrough medications, according to a new report. And Medicaid patients' spending on drugs rose much faster in states that expanded Medicaid under the ACA compared with those that did not.

When it comes to pricing Sovaldi, how NICE of them

By Merrill Goozner  |  March 17, 2015

New cost-effectiveness analyses of Sovaldi and other treatments to treat chronic hepatitis C infection suggest U.S. firms initially set prices near the ceiling that the United Kingdom's National Health Service will pay for drugs.

Study weighs debt financing for pricey breakthrough drugs

By Steven Ross Johnson  |  March 11, 2015

The emergence of new specialty breakthrough medications has come with a hefty price tag that may demand alternative financing approaches to ensure they remain accessible to patients, a new analysis suggests.

The high price of precision medicine

The high price of precision medicine

By By  |  March 07, 2015

Financial markets have sent another signal that the coming era of precision or personalized medicine could wind up making cancer care unaffordable for millions of people.

Q&A: 'Imagine if healthcare were priced to consumers'

Q&A: 'Imagine if healthcare were priced to consumers'

By Modern Healthcare  |  February 14, 2015

Mark Ganz, president and CEO of Cambia Health Solutions, a not-for-profit parent of 22 companies offering healthcare products and services, discusses how his companies are seeking to make healthcare more consumer-directed.

Hep C drug price war likely to slow Gilead’s growth

By Jaimy Lee  |  February 06, 2015

The soaring sales and profits reported by Gilead Sciences in 2014 aren't likely to be repeated as the company begins to offer steeper discounts on its blockbuster hepatitis C treatments Sovaldi and Harvoni.

Gilead's 2014 profit margin nears 50%, fueled by hep C drugs

By Jaimy Lee  |  February 03, 2015

Gilead Sciences, the Foster City, Calif.-based drugmaker, said sales of its blockbuster hepatitis C duo topped $3.8 billion in the fourth quarter of 2014, fueling quarterly revenue that doubled to $7.3 billion and $3.5 billion in profits.

Insurers eye pharma discounts beyond hepatitis C

By Bob Herman  |  February 02, 2015

The pricing battle pitting insurers and pharmacy benefit managers against drugmakers over a new breed of high-priced and highly effective treatments for hepatitis C may be a preview of tougher negotiations for coverage of other blockbuster drugs.

Modern Healthcare Daily

The top stories in healthcare business every day

The Modern Healthcare Daily News App provides you with registration-free access to the top trending healthcare business news. It's the only news you need each day.